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Modulation of antibody-mediated glomerular injury in vivo by inter-
leukin-6. We have shown previously that pretreatment with small doses
of bacterial lipopolysaccharide (LPS), human recombinant interleu-
kin-l/3 (hrIL-1/3) and human recombinant tumor necrosis factor-a
(hrTNF) increase injury in the heterologous phase of nephrotoxic
nephritis (NTN). MI three pretreatments induce synthesis of interleu-
kin-6 (IL-6) which in some systems down-regulates synthesis of IL-l
and TNF. We have now investigated the influence of IL-6 on injury in
both heterologous and autologous phases of NTN in rats. Injection of
hrIL-6 in doses sufficient to induce hepatic synthesis of acute phase
proteins (assessed by plasma a2-macroglobulin concentration) had no
effect on glomerular injury in the heterologous phase of NTN (albumin-
uria in NTAb alone 9 6; LPS/NTAb 34 10 and IL-6/NTAb 2 1
mg124 hr, P < 0.001, Wilcoxon test). In contrast, IL-6 pretreatment
partially abrogated the effect of LPS on albumin excretion (NTAb 4
2; LPS/NTAb 85 11 and IL-6/LPS/NTAb 32 6mg124 hr, P < 0.002),
percentage of glomerular capillary thrombi (3 1%; 39 8%; and 6
1%, P < 0.001) and glomerular neutrophil infiltrate (29 3; 58 5; and
34 2 neutrophils/50 glomeruli in section, P <0.001, respectively) at 24
hours. The effect of IL-6 was also evident four hours after induction of
nephritis and was associated with a marked reduction in glomerular
concentration of mRNA for IL-1/3 and TNF, without change in that of
tubulin. Serum TNF concentrations were also significantly reduced at
four hours in IL-6 treated rats. Glomerular macrophage counts were
unaffected by the treatment of IL-6 at four (53 1; 55 3 and 64 7)
or 24 hours (201 12; 198 9 and 202 9, respectively). A single
injection of IL-6 also decreased albumin excretion by 42% in the
autologous phase of NTN, and reduced the prevalence of glomerular
capillary thrombosis by 68%. These results show that IL-6 has signifi-
cant anti-inflammatory properties in this model of antibody mediated
injury in vivo.
Interleukin-6 (IL-6) is a cytokine with a large number of
different functions but whose role in vivo is uncertain. It is
produced in substantial amounts by monocytes/macrophages
[1], especially when stimulated by lipopolysaccharide (LPS),
interleukin-l (IL-i) or tumor necrosis factor-a (TNF) [2, 3]. It is
also produced in smaller amounts by many other cells including
neutrophils [4], endothelial [51, and mesangial cells [2]. It is a
co-mitogen for T cells, and causes terminal differentiation of
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activated B-cells into plasma cells [6]; it also has hematopoietic
effects [7], and may be important in intra- as well as intercellular
signaling.
Early studies suggested that IL-6 might be pro-inflammatory
like IL- 1 and TNF because it shares many of their properties,
including induction of fever [8], and hepatic synthesis of acute
phase proteins [9]. Increased serum concentrations of IL-6
correlate with mortality rate in a variety of situations including
clinical [10] and experimental endotoxemia [8, 11], and passive
immunization against IL-6 has been reported to reduce mortal-
ity in this situation [12]. However, in contrast to IL-i and TNF,
IL-6 does not cause hemodynamic disturbances [13] or other
toxicity even when injected in high doses [14]. It does not
induce tolerance to endotoxin, nor it does influence the toler-
ance induced by IL-l [15]. Furthermore, again unlike IL-l and
TNF, IL-6 does not activate endothelial cells in vitro [16], and
does not induce endothelial cell adhesion molecules, synovial
collagenase, phospholipase A2, nor nitric oxide synthase [17].
It inhibits the proliferation of bone marrow and peritoneal
macrophages in vitro [18]. Moreover, IL-6 has been reported to
down-regulate IL-i and TNF synthesis by LPS stimulated
macrophages in vitro [19] and to abrogate the systemic [20] and
local effects [21, 22] of LPS in vivo.
The present study was designed to determine the effects of
IL-6 pretreatment on an antibody mediated model of acute
inflammation in vivo, using a passive model of nephrotoxic
nephritis (NTN) in rats. The injury in this model is induced by
injection of heterologous antibodies to the glomerular basement
membrane (GBM), and is neutrophil dependent [23]. The use of
this model has two advantages: first, injury can be quantified
accurately, both functionally and morphometically, and related
to the dose of anti-GBM antibody injected, and second, the
injury can be enhanced by pretreatment with small doses of
LPS, IL-i or TNF [24], an effect largely abrogated by passive
immunization against TNF, or IL-1f3 but not IL-la [25]. We
now show that IL-6 pretreatment does not increase injury in the
way that LPS, TNF and IL- 1/3 do, but instead inhibits the effect
of LPS to the same degree as passive immunization against the
cytokines. Such protection is associated with reduced steady
state concentrations of mRNA for IL-l/3 and TNF in inflamed
glomeruli, and of circulating TNF concentrations. These data
demonstrate the therapeutic effect of IL-6 on glomerular injury.
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Methods
Animals
Male Sprague-Dawley rats weighing 180 to 200gwere used in
all the experiments. They were housed individually in metabo-
lism cages for 24-hour urine collections and had free access to
food and water.
Reagents
Rabbit serum containing high titers of antibodies to rat GBM
was prepared as previously described [25]. Immunoglobulin G
(IgG) was purified from the nephrotoxic serum using a staphy-
lococcus protein-A column [26], with special care to avoid
contamination with endotoxin. The resulting IgG (anti-GBM
Ab, nephrotoxic antibody, NTAb) was tested for contamination
with LPS by Limulus amoebocyte lysate assay, and the final
concentration was always less than 50 pg/mI of NTAb. A stock
solution of 2.5 mglml of LPS (Salmonella lyphimurium; Sigma
Chemical Co., St. Louis, Missouri, USA) was prepared and
stored at 4°C until used. Human recombinant IL-6 was prepared
at the Glaxo Institute of Molecular Biology (Geneva), and found
active at a concentration of 0.1 p, as determined by the
hybridoma growth activity of 7TDI cells, with a specific biolog-
ical activity of 2.8 x 1010 units/mg [271. Its endotoxin contents
is less than S pg/mi (Limulus test). The cDNA probes for rat
IL-1J3 and mouse TNF were provided by Dr. Alan Shaw
(Biogen, Geneva). The cDNA probe for human tubulin kal is a
1.6 kb insert subcloned into pSP64 plasmid which was used as
a control to cross hybridize to rat mRNA [28].
Induction of nephrotoxic nephritis
In the heterologous phase, nephritis was induced by a single
intravenous injection of 10 mg of NTAb (nephrotoxic antibody)
in 1 ml. From previous experiments this dose was known to
cause minimal proteinuna in normal rats and severe nephritis in
rats pretreated with an intraperitoneal injection of 0.25 g of
LPS one hour previously. In the autologous phase, nephritis
was induced by a single intravenous injection of 10 mg of NTAb
one week after immunizing all rats with 1 mg of normal rabbit
IgG in Freund's complete adjuvant subcutaneously.
The severity of nephritis was assessed by urinary albumin
excretion, the percentage of glomeruli with capillary thrombi
with at least one thrombus per glomerulus, the number of
neutrophils infiltrating glomeruli, using previously described
methods [24], and by the total number of macrophages per 50
glomeruli in each section.
Immunohistochemical staining for glomerular macrophages
Four micron-thick frozen sections were prepared and cut
from rat kidneys from different experimental groups as well as
from normal rats. These were mounted on poly-L-lysine-coated
glass slides, air dried for about one hour, and then fixed for 10
minutes in cold acetone. The slides were next rehydrated in
PBS (phosphate-buffered saline) and treated for 30 minutes with
hydrogen peroxide in PBS to block endogenous peroxidase
activity and washed again with PBS. Next they were treated
with a 1:50 dilution of blocking normal sheep serum for 30
minutes and then exposed to 1:50 dilution of (ED1) monoclonal
mouse anti-rat macrophage antibody (Serotec, Oxford, UK)
and similar dilutions of control sera. After overnight incubation
in humid chamber at 4°C, the slides were rinsed and washed
three times with PBS, overlaid with peroxidase-conjugated
secondary polyclonal sheep anti-mouse antibody (dilution
1:100) (Amersham International, UK), and incubated one hour,
followed by three additional rinses and washes with PBS. At
this point, sections were overlaid with substrate DAB (3,3'-
Diaminobenzedine tetrahydrochioride dihydrate, 97%; Aldrich
Chemical Co.) with hydrogen peroxide in PBS and incubated
for 15 minutes at room temperature to allow for color develop-
ment. Harris's hematoxylin was used as a counterstain. Gb-
merular macrophages were counted per 50 glomeruli in each
section.
Northern blot analysis
Kidney tissue was collected for mRNA studies after the
lower pole of the left kidney was removed for histology while
the rats under ether anesthesia. This is followed by perfusion
with 50 ml of phosphate buffered saline (PBS) at room temper-
ature and 10 ml of ice cold PBS. Glomeruli were purified from
the rest of the renal tissues by a standard seiving technique (250
mm, 105 mm, 80 mm) with ice cold PBS. Purified glomeruli
were immediately homogenized (Ika-ultra-Turbax T25 Janke
and Kunkal at 24000 rpm) in 4 M guaninidium thiocyanate
solution. Total RNA was purified from the homogenate with the
cesium chloride gradient ultracentrifugation method [29]. Equal
amounts of total glomerular RNA were electrophoresed on a
3.2% formaldehyde, 1 x MOP, 1% agarose gel and transferred
to Genescreen plusTM (New England Nuclear, Boston, Massa-
chusetts, USA), by capillary blot using 10 x SSC solution (1 x
SSC = 15 m'vi trisodium citrate, 150 m sodium chloride). Total
RNA was extracted from a rat spleen four hours following an
intrapentoneal injection of 0.25 pg of LPS, and from LPS-
stimulated cultured bone marrow macrophages which both
were used as positive controls for Northern hybridization.
Filters were pre-hybridized in 50% formamide, 1% SDS, 10%
dextran sulphate, 1 M NaCl and 200 mg/mb denature salmon
testes DNA (Sigma) overnight at 42°C. Complementary DNA
probes were radiolabeled with 32P-CTP with Klenow DNA
polymerase (Sambrook, Fritsch, Maniatis). Filters were hybrid-
ized in the same pre-hybridization buffer at 42°C with radiola-
beled probe overnight. They were washed twice in 1% SDS +
1 x SSC solution at 42°C for 30 minutes, and twice in 1% SDS
+ 0.1 x SSC solution for another 30 minutes at the same
temperature. Some filters were further washed in 1% SDS +
0.01 to 0.1 x SSC solution to reduce background radioactivity.
Washed filters were exposed to X-romat Kodak film with
intensifier screen at room temperature or —70°C for various
durations up to 14 days. Multiple durations of exposure were
made, so that optimally exposed film was available for densit-
ometry. Filters were stripped of radioactivity by washing in
boiling 0.1% SDS and 0.1 x SSC solution before the next
hybridization. The degree of hybridization was assessed by
densitometric scanning (Chromoscan 3, Joye Loebl) of suitable
autoradiographs. Any difference in RNA loading in each lane
was corrected by normalization to the tubulin hybridization.
Measurement of serum TNF
Five hundred microliters of blood were drawn off at each time
point. Blood samples were transferred to endotoxin free tubes,
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Table 1. Effect of a single intravenous injection of hrIL-6, compared with that of LPS and NS, on plasma alpha 2-macroglobulin
concentration and creatinine clearance
Treatment Number of rats
Alpha 2-macroglobulin g/ml
Creatinine clearance
mi/mm
24 hr2 hr 4 hr 8 hr 24 hr
HrIL-6 6 698 19 603 145 1074 102 1865 183° 0.36 0.04
LPS 3 556 29 463 27 1176 361 2177 409° 0.40 0.10
NS 3 278 27 211 39 216 49 298 2 0.38 0.04
Plasma alpha 2-macroglobulin and creatinine clearance at the start of the experiment were 180 15 sg/ml and 0.47 0.10 mI/mm, respectively.
There is no significant difference in creatinine clearance values between all treatments.
a P < 0.001 compared with other values at different times
incubated for 20 minutes at 37°C for blood to clot, and centri-
fuged at 1500 rpm for 15 minutes. The serum was removed and
stored at —20°C until TNF was measured by WEHI 164 clone
13/2F2 bioassay [30].
Assessment of the hepatic acute phase response
The hepatic acute phase response was assessed functionally
by measurement of plasma alpha 2-macroglobulin (a2m) con-
centration as previously described [25].
Creatinine clearance
Both plasma and urine were assayed for creatinine concen-
trations, using a standard colorimetric assay (Beckman autoan-
alyzer) which is specific for creatinine and subject to minimal
interference from endogenous noncreatinine chromogens, and
endogenous creatinine clearance (Car) was calculated in all
rats.
Statistical analysis
The data are presented as means together with standard
errors (SE). The probabilities that differences between the
groups were significant were calculated using Wilcoxon rank
sum test.
Results
Effect of a single intravenous injection of IL-6
A dose of 4 jig of IL-6 was chosen because of its systemic
effect and ability to induce hepatic acute phase response in rats
[31]. IL-6 was administered intravenously because it is more
potent than other routes [9], and to avoid any possible local
effect, especially when given before the intraperitoneal injec-
tion of LPS. Six rats were injected with IL-6 in 1 ml of
pyrogen-free normal saline (NS, and three with 1 ml of NS
alone. Another three rats were injected intraperitoneally with
0.25 jig LPS in I ml of NS as a positive control. Neither IL-6
nor LPS in these doses caused any apparent clinical distur-
bance. Specifically, all the rats remained active and none
developed ruffling of fur, diarrhea or bloody nasal discharge.
However, both reagents caused comparable hepatic synthesis
of acute phase proteins as assessed by plasma concentrations of
a2m which increased from 180 15 to a maximum of 1865
183 jig/mI at 24 hours in the case of IL-6 and to 2177 409
jig/mI with LPS (P < 0.001 Wilcoxon; Table 1). Neither
treatment caused albuminuria or a significant change in endog-
enous creatinine clearance. These results demonstrate that the
preparation of human recombinant IL-6 is active in rats.
Effect of IL-6 on glomerular injury in the heterologous phase
of NTN
Nephritis was induced by a single intravenous injection of 10
mg NTAb in 1 ml of PBS. One hour before the induction of
nephritis group 1 (N = 9) was injected intravenously with 0.5 ml
NS, group 2 (N = 5) with 0.25 jig LPS in 0.5 ml of NS, and
group 3 (N = 8) with 4 jig IL-6 in 0.5 ml of NS. The results are
shown in Table 2. As in our previous studies, LPS pretreatment
significantly increased the antibody mediated injury [24, 25].
The mean albumin excretion increased from 9 6 to 34 10
mg/24 hr (P < 0.05) in LPS treated rats, and the prevalence of
glomerular thrombosis from 0 0 to 46 9% (P < 0.001). The
glomerular neutrophil infiltrate was similarly increased by LPS
pretreatment, being 37 11 and 88 15 neutrophils per 50
glomeruli in each section (P < 0.001) for group 1 and 2 rats,
respectively. By contrast, pretreatment with IL-6 had no de-
tectable effect on glomerular injury when given one hour before
NTAb (Table 2). Because of this, we assessed the effect of LL-6
given at the same time with NTAb, and again it did not enhance
the injury (albuminuria 1 0.4 mg/24 hr). Neither treatment
effected the creatinine clearance, but both increased plasma
concentration of a2m significantly. These results show that
IL-6, unlike IL-i and TNF [24], does not increase injury in this
model, and so we examined whether IL-6 influences the sever-
ity of the LPS effect.
Pretreatment effect of IL-6 on LPS enhanced glomerular
injury in the heterologous phase of NTN
Six rats were intravenously injected with 0.5 ml NS, followed
30 minutes later by 1 ml NS intraperitoneally and one hour later
by 10 mg NTAb intravenously. Eleven rats were given 0.5 ml
NS, 0.25 jig (1 ml) LPS, and 10 mg NTAb using the same times
and routes, and fifteen rats were similarly treated except that 4
jig IL-6 were injected intravenously before LPS and NTAb
instead of NS. Pretreatment with LPS again caused a significant
increase in glomerular injury and this was partially abrogated by
pretreatment with IL-6, which caused a highly significant 60%
reduction in albuminuria (P < 0.002, compared to nephritic rats
preinjected with LPS, Table 2). There was a comparable
reduction in the incidence of glomerular capillary thrombi, and
the glomerular neutrophil infiltrate (Table 2). However, neither
LPS nor IL-6 affected the macrophage infiltration of nephritic
glomeruli at either time point. All the rats developed a vigorous
acute phase response but a2m was significantly higher in those
injected with either LPS or IL-6; however, there was no
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Table 2. Pretreatment effect of hrIL-6 on the heterologous phase of nephrotoxic nephritis in rats
Treatment
Time
hours
Number
of rats
Albuminuria
mg/24 hr and
mg/4 hr
Cr
mi/mm
Alpha 2-rn
izg/m!
GCT
%
Neutrophils/
50 glomeruli
in section
Macrophages/
50 glomeruli
in section
NTAb
LPS + NTAb
hrIL-6 + NTAb
24
24
24
9
5
8
9 6
34 101,,
2 1 1
0.36 0.1
0.44 0.1
0.34 0.03
1221 1181,,
4071 2681
2509 773
0 0
46 Ib
0 OJ
37 11
88 151,,
31 4 J
ND
ND
ND
NTAb
LPS + NTAb
hrIL-6 + LPS + NTAb
24
24
24
6
11
15
4 2
85 lIla
32 6 J
0.42 0.1
0.38 0.1
0.33 0.03
2019 4451
8039 7511
9991 285
3 1
39 8 b
6 1
29 3
58 Sib
34 2J
201 12
198 9
202 9
NTAb 4 4 1 0.3 ND ND 0 0 87 6 53 1
LPS + NTAb
hrIL-6 + LPS + NTAb
4
4
4
4
51 lSlb
3 I I
ND
ND
ND
ND
76 71,,
16 61
177 231,,
72 201
55 3
64 7
In normal rats (N = 8), the total number of macrophages is 35 1 per 50 glomeruli in section. This is unchanged in rats (N = 8) treated with
hrIL-6 alone (33 2). There is no significant difference in the number of macrophages between all treatments. There is also no significant difference
in the C, (creatinine clearance) values between all treatments. Rats were killed either at 24 or 4 hours and albumin excretion was measured
accordingly. Abbreviations are: HrIL-6, human recombinant interleukin-6; NTAb, nephrotoxic antibody (anti-GBM antibody); LPS, bacterial
lipopolysaccharide; and alpha 2m, alpha 2-macroglobulin; ND, not done.
ap <0.002 and bp < o.ool
difference between these two groups (Table 2). Thus IL-6
partially abrogated the enhanced injury provoked by LPS, and
so we examined its effect on IL-l and TNF production.
Effect of IL-6 on IL-1/3 and TNF synthesis
Separate groups of four rats were studied to assess the effect
of IL-6 pretreatment on systemic TNF concentration and on
glomerular TNF and IL-l/3 gene expression in these models.
The rats were killed four hours after induction of nephritis when
the glomerular neutrophil infiltrate was maximal. Even at this
stage albuminuria, glomerular capillary thrombi and neutrophil
infiltrate were significantly less in IL-6 pretreated group (Table
2). IL-ip and TNF mRNA were not detected by Northern
analysis in giomeruli removed from normal rats, but were easily
detected four hours after the induction of nephritis. The degree
of hybridization was substantially increased after LPS pretreat-
ment and this effect was markedly attenuated by IL-6 (Fig. IA)
without change in that of tubulin (Fig. 1B). TNF was not
detected in serum of any of the rats at the start of the
experiment or in rats given NTAb alone (<5 RU/mi). However,
rats injected with LPS one hour before induction of nephritis
had a substantial increase in serum TNF to 538 182 RU/mi
which was significantly less in the IL-6 treated group (148 66
RU/mi, P < 0.05). Thus, glomerular expression of IL-l/3 and
TNF genes was reduced by IL-6, as was systemic TNF synthe-
sis.
Effect of IL-6 in the autologous phase of NTN
The results in the heterologous phase of NTN prompted us to
examine the effect of IL-6 on glomerular injury in the autolo-
gous phase of NTN. Twenty-one rats were immunized subcu-
taneously with 1 mg of normal rabbit IgG in Freund's complete
adjuvent. One week later they were randomized into two
groups and nephritis was induced by a single intravenous
injection of 10 mg of NTAb. One hour before the induction of
nephritis one group (N = 11) was pretreated with a single
intravenous injection of 4 sg IL-6 diluted in 0.5 ml NS and a
second group with 0.5 ml NS. All the rats were killed at 72
hours and urinary albumin excretion (mg/24 hr) was monitored
at 24, 48, and 72 hours after the induction of nephritis. A single
intravenous injection of IL-6 (4 jsg) had 42% less in albumin
excretion at day 1 (from 606 108 mg/24 hr to 356 73 mg/24
hr) and 68% fewer in glomerular thrombi at day 3 (from 41 7%
to 28 6%). However, there was no significant difference in
giomerular cellular influx of either neutrophils or macrophages
when the rats were killed at 72 hours (Table 3). TNF was not
detected in serum of any of the rats at any of time points over
the first 72 hours. The creatinine clearance at the start of the
experiment was 0.60 0.12 mllmin which dropped significantly
after the induction of nephritis to 0.31 0.04 mllmin (P < 0.05),
but was not statistically different from the group pretreated with
IL-6 (0.36 0.01 mi/mm, Table 3). Similarly, there was no
significant difference in plasma a2m concentration between
both groups.
Discussion
Relations between TNF, IL-i, and IL-6 are complicated.
IL-i and TNF stimulate many cell types to synthesize large
amounts of IL-6; these include neutrophils, monocytes, and
glomerular mesangial cells. Conversly, IL-6 down-regulates
IL-i and TNF synthesis by monocytes [191 and macrophages
[22] exposed to LPS. A similar phenomenon has been reported
in vivo in rodents injected with LPS, in whom pretreatment with
IL-6 reduces circulating TNF concentrations, and IL-1,13 gene
expression [20—22]. Whether this is a direct effect on macro-
phages or works indirectly, for example through the pitutary
adreno-cortical axis [32, 331, has not been ascertained. The
situation in vivo is more complex because not all effects of IL-i
and TNF are opposed by IL-6, and some may even be enhanced
by it [34, 35]. It appears in some systems that the timing of
endogenous IL-6 release or exogenous IL-6 administration is
crucial in determining whether IL-6 antagonizes or synergizes
with IL-i [34].
The results reported here show that pretreatment with IL-6,
unlike LPS, IL-l/3, and TNF, does not exacerbate the glomer-
ular injury but instead largely abrogates the IL-i and TNF
dependent effect of LPS in exacerbating injury in this model.
This protection is associated with a significant reduction in
serum TNF concentration and of glomerular expression of
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Fig. 1A. Northern blotting analysis of glomerular mRNA for IL-I 13 and TNF. Northern blotting analysis of glomerular RNA showing the same
blot sequentially probed for IL-l/3, TNF, and tubulin. Samples include glomerular RNA from normal rats killed at 4 hours, rats injected with 0.25
g LPS one killed at four hours and another at 24 hours, and rats injected with NTAb, LPS/NTAb, and IL-6/LPS/NTAb. Splenic RNA from rats
injected with LPS and from bone marrow macrophages stimulated with LPS were the positive control for hybridization. B. Densitometric analysis
of glomerular IL-113 mRNA concentration from Northern blots. Results were expressed as ratios to positive controls; (1) splenic RNA from an LPS
injected rat (left Y axis) and (2) RNA from LPS stimulated bone marrow macrophages (right axis).
Table 3. Pretreatment effect of hrIL-6 on the autologous phase of nephrotoxic nephritis in rats
Treatment
Number
of rats
Aibuminuria mg/24 hr Cr
mI/mm
a2m
g/ml
GCT
%
Neutrophils/
50 glomeruli
Macrophages/
50 glomeruliDay I Day 2 Day 3
NTAb 10 606 108 598 115 812 137 0.31 0.04 11298 3711 41 7 61 9 353 11
IL-6 + NTAb 11 356 73 381 65 602 88 0.36 0.01 9135 2327 28 6 64 8 359 16
All rats were killed at 72 hours following induction of nephritis. Pretreatment with IL-6 caused a 42% drop in albumin excretion and 68% in
glomerular thrombosis (GCT). However, there was no significant difference in glomerular cellular infiltrate at 72 hours. The creatinine clearance
(Ccr) at the start of the experiment was 0.60 0.12 mI/mm which significantly dropped following induction of nephritis (P < 0.05). However,
pretreatment with IL-6 had no effect (P> 0.05). Similarly, there was no significant change in the alpha 2-macroglobulin (a2m) values between both
groups. Abbreviation is NTAb, nephrotoxic antibody (anti-glomerular basement membrane antibody).
IL-l/3 and TNF genes, which confirms the ability of IL-6 to
down-regulate these cytokines in vivo.
Glomerular inflammation in this model results directly from
binding of antibodies to the GBM, which causes transient
neutrophil dependent injury. Neutrophil infiltration of glomeruli
is maximal between four and six hours, and is accompanied by
monocyte infiltration which persists for longer, even after injury
has subsided. It is notable that pretreatment with IL-6 signifi-
cantly reduced glomerular neutrophil infiltration. This effect has
striking parallels with results from two models of acute lung
inflammation [21, 221 in which injury and neutrophil infiltration
were inhibited by IL-6, without effect on the number of glomer-
ular ED! positive macrophages in this or other model of acute
inflammation [22]. They are also in agreement with recent
experiments in which neutrophils but not macrophage infiltra-
tion was inhibited by IL-6 in an LPS induced model of perito-
nitis in rats (Karkar, Tam, and Rees, manuscript in prepara-
tion). Thus, the differential effect of IL-6 on neutrophil and
macrophage migration is a general phenomenon, but whether
this is due to differences in expression of adhesion molecules by
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leukocytes or endothelial cells or to the synthesis of chemotac-
tic cytokines is not known.
Partial abrogation of glomerular injury caused by IL-6 could
be explained by its direct effect on LPS induced TNF and IL-113
synthesis [19]. It is clear from the measurement of circulating
TNF concentrations that IL-6 pretreatment caused a systemic
reduction in TNF synthesis, and we have shown previously that
passive immunization against this cytokine or IL.-l/3 abrogates
the glomerular injury [25]. IL-6 pretreatment also decreased
glomerular concentrations of specific mRNA for IL-1/3 and
TNF which are synthesized in inflamed glomeruli experimen-
tally [36, 37] and in humans [38], and have been shown to
influence injury [24]. Glomerular mesangial cells [39, 40] and
infiltrating leukocytes [37, 41] from rats are both capable of
releasing IL-i and TNF, but the source of specific glomerular
mRNA in our experiments has not been ascertained. Further-
more, it is not possible to say whether the reduced concentra-
tions of specific mRNA (and by inference reduced concentra-
tions of IL-1/3 and TNF) are responsible for reduced injury, or
are merely a consequence of fewer inflammatory leukocytes
within the glomerulus.
Another theoretical possibility is that the effect of IL-6 was
due to stimulation of hepatic synthesis of acute phase proteins
[9], including proteinase inhibitors with anti-inflammatory ef-
fects. It has been shown that a2m and al-proteinase inhibitor,
purified from inflamed rat serum, suppresses rat neutrophil
chemotaxis in vitro [42], and local and systemic injections of
a2m suppress edema and neutrophil infiltrate in carrageenin-
induced inflammation in rats [43]. Deficiency of al-proteinase
inhibitor is associated with glomerulonephritis and emphysema
[44], and synthetic inhibitors of cysteine and serine proteinases
decrease proteinuria in experimental models of nephritis [45].
However, the protective effect of IL-6 in the present study is
unlikely to be explained by increased a2m synthesis as there
was little difference in a2m concentrations between the LPS and
IL-6 pretreated groups.
The demonstration that IL-6 can reduce acute glomerular
inflammation is pertinent because both rat [2, 46] and human
mesangial cells [47, 48] in culture produce copious amounts of
IL-6 when incubated with IL-i and TNF, and IL-6 can be
detected in glomeruli and urine of patients with glomerulone-
phritis [47]. Until now these findings have been interpreted as
suggesting a proinflammatory role in these circumstances, but it
is possible that local synthesis of IL-6 by mesangial cells helps
to down-regulate glomerular injury. However, the situation is
complicated because administration of IL-6 and other agents
such as IL- lra and soluble IL-i receptors that reduce glomer-
ular injury in nephrotoxic nephritis also reduce glomerular
expression of IL-6 (Karkar, Tam, and Rees, manuscript in
preparation). IL-6 has also been reported to induce proliferation
of rat mesangial cells in vitro [46, 47], but this is controversial
[48, 49]. Our findings in the autologous phase injury suggest that
IL-6 may be capable of modulating injury in an active model of
nephritis, but definitive studies using infusions of IL-6 have yet
to be performed.
In conclusion, we have shown that manipulation of the
cytokine network by IL-6 can attenuate antibody-mediated
glomerular injury, and it seems likely that our results could be
extrapolated to other forms of immunologically mediated in-
flammation.
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Appendix. Abbreviations
NTN, nephrotoxic nephritis; GBM, glomerular basement membrane;
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TNF, tumor necrosis factor; LPS, lipopolysaccharide; a2m, alpha
2-macroglobulin.
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